Skip to the page

Data / Drug companies / Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited: 183 products in the FDA NDC directory, labeler code 13668

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Torrent Pharmaceuticals Limited (labeler code 13668) lists 183 products in the FDA National Drug Code Directory, covering 55 finished drugs by generic name. By type: 182 prescription drugs, 1 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 20, 2026.

The request: Watch Torrent Pharmaceuticals Limited (FDA labeler code 13668): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
13668
Products in commercial distribution
183
Packages
629
Finished drugs by generic name
55
Prescription products
182
Over the counter products
0
Controlled substance products
Schedule IV 3, Schedule V 8
Flagged as original packager
163 of 163 products that carry the flag
Started marketing in the last 12 months
24
Products with a marketing end date set
4
Earliest marketing start
September 5, 2007
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)18198.9%
Bulk ingredients10.5%
New drug applications (NDA)10.5%

Products by type

TypeProductsShare
Prescription drugs18299.5%
Bulk ingredients10.5%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet6937.7%
Capsule2915.8%
Tablet, film coated2212%
Tablet, extended release168.7%
Tablet, delayed release84.4%
Tablet, orally disintegrating84.4%
Tablet, coated63.3%
Granule, delayed release52.7%
Ointment31.6%
Cream31.6%
Tablet, chewable31.6%
Capsule, extended release21.1%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Aprepitant13668-748CapsuleGeneric drugs (ANDA)October 20, 2026
Zolpidem Tartrate13668-775CapsuleGeneric drugs (ANDA)June 23, 2026
Macitentan13668-542TabletGeneric drugs (ANDA)June 1, 2026
Ranolazine13668-760Tablet, film coated, extended releaseGeneric drugs (ANDA)May 11, 2026
Ranolazine13668-759Tablet, film coated, extended releaseGeneric drugs (ANDA)May 11, 2026
Lurasidone Hydrochloride13668-737Tablet, film coatedGeneric drugs (ANDA)March 2, 2026
Olanzapine13668-171TabletGeneric drugs (ANDA)February 28, 2026
Olanzapine13668-170TabletGeneric drugs (ANDA)February 28, 2026
Olanzapine13668-169TabletGeneric drugs (ANDA)February 28, 2026
Olanzapine13668-168TabletGeneric drugs (ANDA)February 28, 2026
Olanzapine13668-167TabletGeneric drugs (ANDA)February 28, 2026
Olanzapine13668-166TabletGeneric drugs (ANDA)February 28, 2026
Ergocalciferol13668-757CapsuleNew drug applications (NDA)February 10, 2026
Levetiracetam13668-300Tablet, extended releaseGeneric drugs (ANDA)January 30, 2026
Levetiracetam13668-272Tablet, extended releaseGeneric drugs (ANDA)January 30, 2026
Fidaxomicin13668-745Tablet, film coatedGeneric drugs (ANDA)January 27, 2026
Lamotrigine13668-696Tablet, orally disintegratingGeneric drugs (ANDA)January 8, 2026
Lamotrigine13668-695Tablet, orally disintegratingGeneric drugs (ANDA)January 8, 2026
Lamotrigine13668-694Tablet, orally disintegratingGeneric drugs (ANDA)January 8, 2026
Lamotrigine13668-693Tablet, orally disintegratingGeneric drugs (ANDA)January 8, 2026
Nilotinib13668-711CapsuleGeneric drugs (ANDA)December 16, 2025
Nilotinib13668-710CapsuleGeneric drugs (ANDA)December 16, 2025
Rasagiline13668-447TabletGeneric drugs (ANDA)November 15, 2025
Rasagiline13668-446TabletGeneric drugs (ANDA)November 15, 2025
Sucralfate13668-754SuspensionGeneric drugs (ANDA)September 15, 2025

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.